Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Castaigne

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Agents and Actions. Supplements|January 1, 1984
Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisisJ Lonsdorfer, J P Castaigne, E Lenormand, et al.
Lancet (London, England)|November 7, 1987
Recombinant erythropoietin and blood pressureC Jacquot, M Ferragu-Haguet, A Lefebvre, et al.
British Journal of Pharmacology|June 25, 2008
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2A Régina, M Demeule, C Ché, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 17, 2008
Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjectsR G Tiessen, J P Castaigne, J F Dreyfus, et al.
Lancet (London, England)|December 6, 1986
Erythropoietin treatment in anaemic patients on haemodialysisB Zins, T Drüeke, J Zingraff, et al.
Advances in Nephrology From the Necker Hospital|January 1, 1989
Utilization of erythropoietin in the treatment of the anemia due to chronic renal failureT Drüeke, B Zins, C Naret, et al.
British Journal of Cancer|October 27, 2011
Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1Y Bertrand, J-C Currie, J Poirier, et al.
Transplantation|October 15, 1995
Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantationP L Amlot, E Rawlings, O N Fernando, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Agents and Actions. Supplements|January 1, 1984
Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisisJ Lonsdorfer, J P Castaigne, E Lenormand, et al.
Lancet (London, England)|November 7, 1987
Recombinant erythropoietin and blood pressureC Jacquot, M Ferragu-Haguet, A Lefebvre, et al.
British Journal of Pharmacology|June 25, 2008
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2A Régina, M Demeule, C Ché, et al.
International Journal of Clinical Pharmacology and Therapeutics|September 17, 2008
Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjectsR G Tiessen, J P Castaigne, J F Dreyfus, et al.
Lancet (London, England)|December 6, 1986
Erythropoietin treatment in anaemic patients on haemodialysisB Zins, T Drüeke, J Zingraff, et al.
Advances in Nephrology From the Necker Hospital|January 1, 1989
Utilization of erythropoietin in the treatment of the anemia due to chronic renal failureT Drüeke, B Zins, C Naret, et al.
British Journal of Cancer|October 27, 2011
Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1Y Bertrand, J-C Currie, J Poirier, et al.
Transplantation|October 15, 1995
Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantationP L Amlot, E Rawlings, O N Fernando, et al.
Pageof 2